Get the Stockscreener App
577.95
0.39%
2.26
After Hours:
578.00
0.05
+0.01%
Regeneron Pharmaceuticals Inc stock is traded at $577.95, with a volume of 875.20K.
It is up +0.39% in the last 24 hours and up +0.17% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$575.69
Open:
$579.65
24h Volume:
875.20K
Relative Volume:
0.86
Market Cap:
$60.21B
Revenue:
$14.21B
Net Income/Loss:
$4.46B
P/E Ratio:
14.56
EPS:
39.6877
Net Cash Flow:
$3.56B
1W Performance:
-0.02%
1M Performance:
+0.17%
6M Performance:
-3.64%
1Y Performance:
-37.78%
1-Day Range:
$576.20
$582.70
1-Week Range:
$572.75
$588.71
52-Week Range:
$476.49
$943.83
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Can Regeneron Pharmaceuticals Inc. stock hit record highs againJuly 2025 Trends & Weekly Return Optimization Alerts - newser.com
What does recent volatility data suggest for Regeneron Pharmaceuticals Inc.Earnings Risk Report & High Return Stock Watch Alerts - newser.com
Long Leaf Partners Fund’s Comment on Regeneron (REGN) - Insider Monkey
What MACD signals say about Regeneron Pharmaceuticals Inc.Quarterly Earnings Summary & Community Consensus Stock Picks - newser.com
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? - The Globe and Mail
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move - BioSpace
Sanofi higher after Q3 beat driven by Regeneron-partnered Dupixent - MSN
Combining price and volume data for Regeneron Pharmaceuticals Inc.Market Performance Summary & Capital Protection Trading Alerts - newser.com
Heatmap analysis for Regeneron Pharmaceuticals Inc. and competitorsWeekly Profit Summary & AI Powered Trade Plan Recommendations - newser.com
Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged - Reuters
December 5th Options Now Available For Regeneron Pharmaceuticals (REGN) - Nasdaq
Canaccord Genuity Maintains Buy Rating on REGN with $850 Target - GuruFocus
Schaper Benz & Wise Investment Counsel Inc. WI Has $11.74 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Boosts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Canaccord Genuity Group Reaffirms Buy Rating for Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS - Yahoo Finance
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Increased by Ethic Inc. - MarketBeat
Cullen Frost Bankers Inc. Sells 445 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Neutralizing Antibody Market Set for Dynamic Development with - openPR.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is a strong buy callJuly 2025 News Drivers & Safe Entry Trade Signal Reports - newser.com
United States Non-Opioid Pain Treatment Market 2025: Recent - openPR.com
A Look at Regeneron (REGN) Valuation Following Key Libtayo Approval and Gene Therapy Milestones - simplywall.st
ARK Investment Management LLC Sells 1,088 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Private Capital Advisors Inc. Takes $323,000 Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Expediting Review of Regeneron Drug to Treat Genetic Hearing Loss - The Hearing Review
Regeneron, Rival End Patent Fight Over Eye Med Biosimilar - Law360
Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Regeneron Pharmaceuticals (REGN) Joins ClearBridge's Select Stra - GuruFocus
Celltrion Settlement Provides US Date For Aflibercept Entry - Citeline News & Insights
United States Retinal Biologics: AMD & Diabetic Retinopathy - openPR.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by DekaBank Deutsche Girozentrale - MarketBeat
Regeneron Pharmaceuticals (REGN) to Release Quarterly Earnings on Tuesday - MarketBeat
Is Regeneron Pharmaceuticals Inc. stock resilient to inflationPortfolio Value Report & Long Hold Capital Preservation Tips - newser.com
Detecting support and resistance levels for Regeneron Pharmaceuticals Inc.Market Activity Recap & Verified Entry Point Signals - newser.com
Why analysts raise outlook for Regeneron Pharmaceuticals Inc. (RGO) stock2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Regeneron and Celltrion Settle Eylea Biosimilar Patent Fight - Bloomberg Law News
How sentiment analysis helps forecast Regeneron Pharmaceuticals Inc.2025 Winners & Losers & AI Driven Stock Reports - newser.com
New DB-OTO Results Show Sustained Improvements for Children with Profound Genetic Hearing Loss - The Hearing Review
Will Regeneron Pharmaceuticals Inc. continue its uptrendJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $27.85 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Biotech Giant with 25% Potential Upside - DirectorsTalk Interviews
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MSN
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):